Regeneron Pharmaceuticals, Inc. $REGN Holdings Lessened by Sepio Capital LP

Sepio Capital LP lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.6% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 3,639 shares of the biopharmaceutical company’s stock after selling 778 shares during the quarter. Sepio Capital LP’s holdings in Regeneron Pharmaceuticals were worth $2,760,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at $5,682,636,000. Legal & General Group Plc bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $473,872,000. Bank of New York Mellon Corp bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $472,950,000. Deutsche Bank AG purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $323,249,000. Finally, Man Group plc purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $272,460,000. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the transaction, the insider directly owned 47,833 shares of the company’s stock, valued at $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at $512,550. This trade represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $819.09 on Friday. The company has a market cap of $84.33 billion, a price-to-earnings ratio of 20.24, a PEG ratio of 1.37 and a beta of 0.16. The firm’s fifty day moving average is $791.83 and its 200 day moving average is $722.58. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52-week low of $572.75 and a 52-week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the business earned $12.81 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% compared to the same quarter last year. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 48.87 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Analysts Set New Price Targets

Several research firms have commented on REGN. Robert W. Baird increased their price objective on shares of Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a “neutral” rating in a report on Friday, July 31st. JPMorgan Chase & Co. lifted their target price on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the stock an “overweight” rating in a report on Tuesday, October 6th. Evercore boosted their target price on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. The Goldman Sachs Group boosted their target price on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $846.28.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.